Several of these denials appear to rest on coverage rules that don't actually say what the plan is treating them as saying. That's better news than it sounds — a legal error is easier to overturn than a clinical disagreement.
This is research on coverage rules, not medical advice. Which treatment is right is a question for the treating physicians. What's below is about how the payment rules work, where they're being misapplied, and what specifically to put in front of the plan.
The premise that osteoporosis drugs were all developed for women is only partly true in 2026 — and the difference matters enormously for appeals. Six of the nine major drugs now carry FDA-approved indications for men.
| Drug | Approved for men? | Which benefit pays |
|---|---|---|
| Tymlos (abaloparatide) | Yes — since December 2022, with no qualifying language | Part D — pharmacy side |
| Forteo (teriparatide) | Yes, but limited to "primary or hypogonadal" osteoporosis | Part D — pharmacy side |
| Prolia (denosumab) | Yes — since September 2012 | Part B — medical side |
| Reclast (zoledronic acid) | Yes — since 2009 | Part B — medical side |
| Alendronate, risedronate | Yes | Part D |
| Evenity (romosozumab) | No — postmenopausal women only | Part B — medical side |
| Ibandronate, raloxifene | No | Part D |
The February 8, 2025 denial of Evenity is taken apart in detail on its own page, including draft language for the prescriber's letter. Short version: the denial applied a Part D test to what is actually a Part B drug, and UnitedHealthcare's own published policies say so. Read it →
Its FDA label covers "men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy." A man with congenital osteoporosis, decades of bisphosphonate exposure, and fractures meets both independent prongs.
This should be filed as a standard prior authorization for an approved indication — not as an exception request or an off-label appeal. Framing matters: conceding "off-label" hands the plan a much easier denial.
Note the contrast with Forteo, whose "primary or hypogonadal" wording gives a reviewer an opening to argue congenital osteoporosis is neither. That is a reason to lead with Tymlos.
Tymlos and Forteo run through the pharmacy benefit — coverage determination, 72 hours standard, 24 expedited.
Prolia, Reclast, and Evenity run through the medical benefit — organization determination, 7 days standard, 72 hours expedited.
Different forms, different departments, different deadlines. A request sent to the wrong one can sit for weeks before anyone says so.
There is a narrow Medicare benefit for injectable osteoporosis drugs delivered through home health that genuinely is written for women only. It has nothing to do with ordinary coverage of a drug given in a doctor's office, which is entirely sex-neutral. Plans and reviewers conflate the two.
If a denial letter applies a "fracture related to post-menopausal osteoporosis" criterion to an office infusion, saying so explicitly — that this is an incorrect application of Medicare coverage rules, which the plan is required to follow — is a strong and specific appeal ground.
Under 42 CFR 422.136, a Medicare Advantage plan may apply step therapy to office-administered drugs only for new administrations, using at least a 365-day lookback period. If he received the drug within the past year, step therapy cannot be applied. That's a clean procedural win when it applies.
And more broadly: years of fractures while on bisphosphonates is step therapy — already completed, already failed. Fracture while on approved therapy is the textbook definition of treatment failure. Requiring another trial of the same mechanistic class isn't a medically reasonable alternative, and it carries real cumulative risk from prolonged bisphosphonate exposure.
If the underlying diagnosis is osteogenesis imperfecta, it usefully explains why decades of bisphosphonates didn't fix the problem — a collagen defect isn't correctable by suppressing bone resorption. But it should be the secondary code, not the primary one.
The OI code (Q78.0) is not on Medicare's covered diagnosis list for these drugs, so a claim coded primarily to it can be rejected on coding grounds before anyone reads the clinical argument. The osteoporosis codes — M81.8, or M80.8- if there's a current fracture — are on the covered list. Avoid M81.0 ("age-related"), which is both inaccurate and undercuts the whole argument.
This is worth raising directly with the prescribing office. It's a five-minute fix that resolves some denials outright.
The eye involvement is most likely neurotrophic keratitis. The ophthalmic branch of the trigeminal nerve supplies essentially all corneal sensation, and when it's damaged the cornea loses both feeling and the trophic signals that keep it healthy — so damage progresses without pain to warn of it.
The medical literature identifies procedures done to treat trigeminal neuralgia — microvascular decompression, gamma knife, alcohol blocks, radiofrequency rhizotomy — as recognized causes of neurotrophic keratitis. If any of those were performed, this isn't an unrelated eye problem; it's a documented complication of covered treatment. That's a far stronger footing than a general medical-necessity argument, and it should be stated explicitly in the letter.
| Product | Coverage | What to know |
|---|---|---|
| Oxervate (cenegermin) | Part D, specialty tier | Winnable. Criteria typically require Stage 2 or 3 disease documented, failure of at least one artificial tear, and prescription by or with an eye specialist. Approved as a single 8-week course. Dispensed through a specialty pharmacy with cold-chain delivery — a refusal at a retail counter is often a channel problem, not a coverage denial. |
| Autologous serum tears | Neither Part B nor Part D | Made from the patient's own blood, so it isn't an FDA-approved drug product and cannot meet the Part D definition. The American Academy of Ophthalmology states plainly that most payers have no allowable for it. Expect cash pay — and don't spend appeal energy here. The venipuncture and office visit are separately covered. |
| Compounded drops | Usually neither | Compounded eye drops are typically made from bulk chemical ingredients, which by rule are not Part D drugs. This is a manual-level bar, so a formulary exception cannot fix it. Workaround: ask whether the compounder can prepare it from an FDA-approved commercial product instead of bulk powder. That changes the answer. |
| Restasis, Xiidra, Cequa, Miebo | Part D | Step therapy — typically must fail two others first. See the traps below. |
| Amniotic membrane | Part B — medical | Not a drug, so it bypasses the pharmacy benefit entirely. A genuine route to treating this that avoids the formulary problem. Worth raising with the ophthalmologist. |
| Scleral / bandage lenses | Part B — prosthetic | Commonly missed. A mainstay of managing this condition, billed medically rather than through the pharmacy. |
| Punctal plugs, tarsorrhaphy | Part B | In-office procedures, covered. |
The wrong diagnosis code may be on the claim. If a drop is submitted under a dry eye code, the plan's dry-eye step-therapy policy applies. Submitted under a neurotrophic keratitis code, that policy arguably doesn't apply at all. Find out which code was actually on the denied claim. A miscoded diagnosis is among the most common and most fixable causes of these denials.
The "monotherapy" clause is clinically inapplicable here. Dry-eye policies commonly require that the drug "not be used in combination with another prescription product for dry eye disease." Someone with neurotrophic keratitis legitimately needs several agents concurrently. That criterion was written for ordinary dry eye, and pointing out that it produces an automatic denial of appropriate care for this condition is a strong argument in itself.
Oxervate runs into the tens of thousands of dollars per course. But the 2026 Part D out-of-pocket cap is $2,100. Once it is approved, a single course blows through that cap almost immediately — and every other prescription for the rest of that calendar year costs $0, including the anticonvulsants.
That inverts the usual calculation: fighting for approval is worth far more than the effort it takes, because approval effectively zeroes out the rest of the year's drug costs. Also ask about the Medicare Prescription Payment Plan, which spreads that $2,100 across monthly installments rather than one January hit.
Carbamazepine is the one drug here specifically FDA-approved for trigeminal neuralgia. Oxcarbazepine, gabapentin, baclofen, and lamotrigine are all technically off-label for TN. They rarely get denied because they're inexpensive — but if one is, the denial reason will be "not a medically accepted indication," and the correct rebuttal is a compendium citation, not a medical necessity letter. Ask the plan which compendium they checked. A quantity limit denial is a different animal entirely and goes through the exception process on medical necessity grounds — TN doses do run high, so this comes up.
Texas is one of six states in Medicare's WISeR pilot, which since January 2026 has applied prior authorization to Original Medicare for a short list of services — including nerve stimulators and certain induced lesions of nerve tracts, which may capture some TN procedures. It remains narrow, and nothing like what Medicare Advantage does. But it's not zero, and it's worth knowing before assuming Original Medicare is a complete escape.
Surveillance after bladder cancer is designed to be indefinite — recurrence rates are high, so cystoscopy and imaging continue for years. Under Original Medicare, surveillance cystoscopy and CT urography are not prior-authorized. Under Medicare Advantage they typically are, which means an ongoing series of approval events for tests that are simply standard of care.
Worth also checking: if ostomy or urological supplies are involved, those are durable medical equipment under Part B. Medicare Advantage plans frequently prior-authorize them and restrict which suppliers you may use, where Original Medicare largely does not.
Ongoing surveillance is precisely what makes individual Medigap unobtainable. Carriers ask whether you have been "advised by a physician to have treatment, follow-up visits, further diagnostic evaluation, diagnostic testing or therapy" — with no time limit on the question. A standing surveillance schedule answers yes indefinitely, independent of any cancer look-back period.
This is the main reason Option 3 — leaving Valero for individual Medigap — is likely closed for now. It's not a reason to stop surveillance; it's a reason to plan around a different route.